MD-265

Overview

MD-265 is a PROTAC degrader targeting MDM2 , which activates p53 in cancer cells carrying wild-type p53 . MD-265 induces MDM2 degradation by recruiting the CRL4-CRBN ligase complex via the ubiquitination and proteasomal degradation pathway. MD-265 upregulates p53 target genes, induces apoptosis , reduces Mcl-1 levels, increases caspase-3 cleavage, and inhibits colony formation of wild-type p53 leukemia stem cells. MD-265 can be used in research related to leukemia and acute myeloid leukemia. (Pink: MDM-2/p53 ligand ( HY-133754 ); Blue: Cereblon ligand ( HY-A0003 ); Black: linker).

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-169327
• CAS No.: 2415160-21-1
• Molecular Formula: C50H51Cl2FN6O6
• Molecular Weight: 921.88
• Purity: 99.31%
• Storage: -20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Availability: In-stock

Source

Original product source